Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Peter McHugh of the Department of Oncology has been awarded a 4 year grant from the Medical Research Council.

The news comes hot on the heels of Professor McHugh's Cancer Research UK programme award. Grant success is tough, so this is a truly impressive achievement.

The MRC funded work focusses on the repair of DNA interstrand crosslinks (ICLs), which are formed when the two strands of the DNA double-helix become covalently linked together. ICLs are an extremely toxic form of DNA damage that prevent cellular fundamental processes including DNA replication and transcription. Defects in ICL repair result in cancer pre-disposition syndromes, such as Fanconi anemia, underlining the importance of ICL repair in human development and cancer avoidance.

Conversely, many important cancer chemotherapeutics work through ICL formation. Together, these facts emphasise the importance of understanding ICL repair for improving cancer prevention and treatment strategies.

Professor McHugh said of the project: "Here, the team aim to understand the nucleases and associated proteins that act to incise the DNA during ICL repair, with a focus on the XPF(FANCQ)-ERCC1 endonuclease, and the associated SLX4(FANCP) factor. We are using a combination of biochemical and structural approaches to reveal how these nuclease complexes are delivered to sites of DNA damage during DNA replication, and to characterise the reactions they undertake to initiate DNA repair at the replication fork."

Congratulations Professor McHugh and good luck with the research.

Similar stories

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

Eileen Parkes secures Clinical Research Career Development Fellowship

Eileen is awarded funding for her research into the tumour microenvironment

Further funding secured to hunt out cancer using innovative radiotherapy techniques

Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.